The only thing I would add is that for those assets that are not drugs and that provinces and territories can procure and require to maintain their own stockpile and surge capacity effectively, we're that secondary surge piece. We work very closely with them to ensure that we are buying products that meet the performance and technical specifications that will ensure it is easy to integrate those into the health care system. We had the example earlier with the NIOSH N95 respirators.
Ensuring that something can be deployed rapidly to support that surge need is another layer in how we ensure that we're getting best value for dollar.